AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Top Analysts Upgrade Stocks: AVITA Medical, Agios Pharmaceuticals, Nasdaq, Marsh & McLennan, Parsons
ByAinvest
Thursday, Nov 20, 2025 12:23 pm ET1min read
Several top Wall Street analysts have upgraded their ratings for various stocks, including AVITA Medical (RCEL), Agios Pharmaceuticals (AGIO), Nasdaq (NDAQ), Marsh & McLennan Companies (MMC), and Parsons Corp (PSN). BTIG analyst Ryan Zimmerman upgraded AVITA Medical from Sell to Neutral, while Leerink Partners analyst Andrew Berens upgraded Agios Pharmaceuticals from Market Perform to Outperform. Morgan Stanley analyst Michael Cyprys upgraded Nasdaq from Equal-Weight to Overweight and raised the price target from $97 to $110. Barclays analyst Alex Scott upgraded Marsh & McLennan Companies from Equal-Weight to Overweight and lowered the price target from $221 to $206. William Blair analyst Louie DiPalma upgraded Parsons Corp from Market Perform to Outperform.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet